Dynamics of leukemia stem-like cell extinction in acute promyelocytic leukemia

Benjamin Werner, Robert E. Gallagher, Elisabeth M. Paietta, Mark R. Litzow, Martin S. Tallman, Peter H. Wiernik, James L. Slack, Cheryl L. Willman, Zhuoxin Sun, Arne Traulsen, David Dingli

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Many tumors are believed to be maintained by a small number of cancer stem-like cells, where cure is thought to require eradication of this cell population. In this study, we investigated the dynamics of acute promyelocytic leukemia (APL) before and during therapy with regard to disease initiation, progression, and therapeutic response. This investigation used a mathematical model of hematopoiesis and a dataset derived from the North American Intergroup Study INT0129. The known phenotypic constraints of APL could be explained by a combination of differentiation blockade of PML-RARa-positive cells and suppression of normal hematopoiesis. All-trans retinoic acid (ATRA) neutralizes the differentiation block and decreases the proliferation rate of leukemic stem cells in vivo. Prolonged ATRA treatment after chemotherapy can cure patients with APL by eliminating the stem-like cell population over the course of approximately one year. To our knowledge, this study offers the first estimate of the average duration of therapy that is required to eliminate stem-like cancer cells from a human tumor, with the potential for the refinement of treatment strategies to better manage human malignancy.

Original languageEnglish (US)
Pages (from-to)5386-5396
Number of pages11
JournalCancer Research
Volume74
Issue number19
DOIs
StatePublished - Oct 1 2014

Fingerprint

Acute Promyelocytic Leukemia
Leukemia
Stem Cells
Neoplastic Stem Cells
Hematopoiesis
Tretinoin
Therapeutics
Neoplasms
Population
Disease Progression
Theoretical Models
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Werner, B., Gallagher, R. E., Paietta, E. M., Litzow, M. R., Tallman, M. S., Wiernik, P. H., ... Dingli, D. (2014). Dynamics of leukemia stem-like cell extinction in acute promyelocytic leukemia. Cancer Research, 74(19), 5386-5396. https://doi.org/10.1158/0008-5472.CAN-14-1210

Dynamics of leukemia stem-like cell extinction in acute promyelocytic leukemia. / Werner, Benjamin; Gallagher, Robert E.; Paietta, Elisabeth M.; Litzow, Mark R.; Tallman, Martin S.; Wiernik, Peter H.; Slack, James L.; Willman, Cheryl L.; Sun, Zhuoxin; Traulsen, Arne; Dingli, David.

In: Cancer Research, Vol. 74, No. 19, 01.10.2014, p. 5386-5396.

Research output: Contribution to journalArticle

Werner, B, Gallagher, RE, Paietta, EM, Litzow, MR, Tallman, MS, Wiernik, PH, Slack, JL, Willman, CL, Sun, Z, Traulsen, A & Dingli, D 2014, 'Dynamics of leukemia stem-like cell extinction in acute promyelocytic leukemia', Cancer Research, vol. 74, no. 19, pp. 5386-5396. https://doi.org/10.1158/0008-5472.CAN-14-1210
Werner, Benjamin ; Gallagher, Robert E. ; Paietta, Elisabeth M. ; Litzow, Mark R. ; Tallman, Martin S. ; Wiernik, Peter H. ; Slack, James L. ; Willman, Cheryl L. ; Sun, Zhuoxin ; Traulsen, Arne ; Dingli, David. / Dynamics of leukemia stem-like cell extinction in acute promyelocytic leukemia. In: Cancer Research. 2014 ; Vol. 74, No. 19. pp. 5386-5396.
@article{885bc34ab5f64c7596f064b08739357f,
title = "Dynamics of leukemia stem-like cell extinction in acute promyelocytic leukemia",
abstract = "Many tumors are believed to be maintained by a small number of cancer stem-like cells, where cure is thought to require eradication of this cell population. In this study, we investigated the dynamics of acute promyelocytic leukemia (APL) before and during therapy with regard to disease initiation, progression, and therapeutic response. This investigation used a mathematical model of hematopoiesis and a dataset derived from the North American Intergroup Study INT0129. The known phenotypic constraints of APL could be explained by a combination of differentiation blockade of PML-RARa-positive cells and suppression of normal hematopoiesis. All-trans retinoic acid (ATRA) neutralizes the differentiation block and decreases the proliferation rate of leukemic stem cells in vivo. Prolonged ATRA treatment after chemotherapy can cure patients with APL by eliminating the stem-like cell population over the course of approximately one year. To our knowledge, this study offers the first estimate of the average duration of therapy that is required to eliminate stem-like cancer cells from a human tumor, with the potential for the refinement of treatment strategies to better manage human malignancy.",
author = "Benjamin Werner and Gallagher, {Robert E.} and Paietta, {Elisabeth M.} and Litzow, {Mark R.} and Tallman, {Martin S.} and Wiernik, {Peter H.} and Slack, {James L.} and Willman, {Cheryl L.} and Zhuoxin Sun and Arne Traulsen and David Dingli",
year = "2014",
month = "10",
day = "1",
doi = "10.1158/0008-5472.CAN-14-1210",
language = "English (US)",
volume = "74",
pages = "5386--5396",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - Dynamics of leukemia stem-like cell extinction in acute promyelocytic leukemia

AU - Werner, Benjamin

AU - Gallagher, Robert E.

AU - Paietta, Elisabeth M.

AU - Litzow, Mark R.

AU - Tallman, Martin S.

AU - Wiernik, Peter H.

AU - Slack, James L.

AU - Willman, Cheryl L.

AU - Sun, Zhuoxin

AU - Traulsen, Arne

AU - Dingli, David

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Many tumors are believed to be maintained by a small number of cancer stem-like cells, where cure is thought to require eradication of this cell population. In this study, we investigated the dynamics of acute promyelocytic leukemia (APL) before and during therapy with regard to disease initiation, progression, and therapeutic response. This investigation used a mathematical model of hematopoiesis and a dataset derived from the North American Intergroup Study INT0129. The known phenotypic constraints of APL could be explained by a combination of differentiation blockade of PML-RARa-positive cells and suppression of normal hematopoiesis. All-trans retinoic acid (ATRA) neutralizes the differentiation block and decreases the proliferation rate of leukemic stem cells in vivo. Prolonged ATRA treatment after chemotherapy can cure patients with APL by eliminating the stem-like cell population over the course of approximately one year. To our knowledge, this study offers the first estimate of the average duration of therapy that is required to eliminate stem-like cancer cells from a human tumor, with the potential for the refinement of treatment strategies to better manage human malignancy.

AB - Many tumors are believed to be maintained by a small number of cancer stem-like cells, where cure is thought to require eradication of this cell population. In this study, we investigated the dynamics of acute promyelocytic leukemia (APL) before and during therapy with regard to disease initiation, progression, and therapeutic response. This investigation used a mathematical model of hematopoiesis and a dataset derived from the North American Intergroup Study INT0129. The known phenotypic constraints of APL could be explained by a combination of differentiation blockade of PML-RARa-positive cells and suppression of normal hematopoiesis. All-trans retinoic acid (ATRA) neutralizes the differentiation block and decreases the proliferation rate of leukemic stem cells in vivo. Prolonged ATRA treatment after chemotherapy can cure patients with APL by eliminating the stem-like cell population over the course of approximately one year. To our knowledge, this study offers the first estimate of the average duration of therapy that is required to eliminate stem-like cancer cells from a human tumor, with the potential for the refinement of treatment strategies to better manage human malignancy.

UR - http://www.scopus.com/inward/record.url?scp=84907482235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907482235&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-14-1210

DO - 10.1158/0008-5472.CAN-14-1210

M3 - Article

VL - 74

SP - 5386

EP - 5396

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 19

ER -